Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH)
Abstract
OBJECTIVE: The male lower urinary tract symptoms (LUTS) panel of the French Urological Association (AFU) aimed to update the 2012 French guidelines for pharmacological treatment of LUTS secondary to benign prostatic hyperplasia (BPH). METHODS: A systematic review of articles published between 2012 and 2024 was conducted in PubMed® to update the previous guidelines. The methodology included a predefined search strategy, critical appraisal of the literature with assignment of evidence levels, and the development of evidence-based conclusions and recommendations. RESULTS/RECOMMENDATIONS: Monitoring may be offered to patients with mild to moderate LUTS who are not bothered by their symptoms. Men with LUTS should be offered lifestyle and dietary advice before or when initiating treatment. Alpha-blockers may be offered to patients with moderate to severe LUTS as first-line therapy. 5-alpha-reductase inhibitors (5-ARIs) may be offered to patients with moderate to severe LUTS and prostate volume above 40mL, though their therapeutic benefit requires sustained long-term administration. Combination therapy with alpha-blockers and 5-ARIs is indicated for moderate to severe LUTS when prostate volume exceeds 40mL. Serenoa repens in its hexanic extract formulation may be considered for mild to moderate LUTS. Antimuscarinics or beta-3 agonists may be offered to patients with moderate to severe LUTS and predominant storage symptoms as second-line therapy. Tadalafil alone or combined with alpha-blockers is recommended for moderate to severe LUTS, particularly when erectile dysfunction coexists. CONCLUSION: These recommendations provide urologists with evidence-based guidance for more personalized management of BPH-related LUTS.
Related
- Effects of Lindera aggregata Linderae Radix on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats
- Endoplasmic reticulum–mitochondria contact sites in benign prostatic hyperplasia: evidence integration and mechanistic hypotheses
- THz Spectroscopy of Urine Vapors from Patients with Prostate Cancer and Benign Prostatic Hyperplasia: A Critical Review and Statistical Reanalysis
- Treatment of interstitial cystitis/bladder pain syndrome: Guidelines from the Committee of Female Urology (CUROPF) of the French Association of Urology (AFU)
- Diagnosis of interstitial cystitis/bladder pain syndrome: Guidelines from the Committee of Female Urology (CUROPF) of the French Association of Urology (AFU)
BibTeX
@article{anract2026noninterventional,
title = {{Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH)}},
author = {Julien Anract and Clément Klein and Clément Sarrazin and Ugo Pinar and Armand Chevrot and Hakim Fassi-Fehri and Jonas Wilisch and Jérôme Gas and Yohann Rouscoff and Emmanuel Della Negra and Steeve Doizi and Souhil Lebdai},
journal = {The French Journal of Urology},
year = {2026},
month = oct,
doi = {10.1016/j.fjurol.2025.102952},
url = {https://hal.science/hal-05796098v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH)
AU - Julien Anract
AU - Clément Klein
AU - Clément Sarrazin
AU - Ugo Pinar
AU - Armand Chevrot
AU - Hakim Fassi-Fehri
AU - Jonas Wilisch
AU - Jérôme Gas
AU - Yohann Rouscoff
AU - Emmanuel Della Negra
AU - Steeve Doizi
AU - Souhil Lebdai
PY - 2026
DA - 2026/10/12
JO - The French Journal of Urology
DO - 10.1016/j.fjurol.2025.102952
UR - https://hal.science/hal-05796098v1
AB - OBJECTIVE: The male lower urinary tract symptoms (LUTS) panel of the French Urological Association (AFU) aimed to update the 2012 French guidelines for pharmacological treatment of LUTS secondary to benign prostatic hyperplasia (BPH). METHODS: A systematic review of articles published between 2012 and 2024 was conducted in PubMed® to update the previous guidelines. The methodology included a predefined search strategy, critical appraisal of the literature with assignment of evidence levels, and the development of evidence-based conclusions and recommendations. RESULTS/RECOMMENDATIONS: Monitoring may be offered to patients with mild to moderate LUTS who are not bothered by their symptoms. Men with LUTS should be offered lifestyle and dietary advice before or when initiating treatment. Alpha-blockers may be offered to patients with moderate to severe LUTS as first-line therapy. 5-alpha-reductase inhibitors (5-ARIs) may be offered to patients with moderate to severe LUTS and prostate volume above 40mL, though their therapeutic benefit requires sustained long-term administration. Combination therapy with alpha-blockers and 5-ARIs is indicated for moderate to severe LUTS when prostate volume exceeds 40mL. Serenoa repens in its hexanic extract formulation may be considered for mild to moderate LUTS. Antimuscarinics or beta-3 agonists may be offered to patients with moderate to severe LUTS and predominant storage symptoms as second-line therapy. Tadalafil alone or combined with alpha-blockers is recommended for moderate to severe LUTS, particularly when erectile dysfunction coexists. CONCLUSION: These recommendations provide urologists with evidence-based guidance for more personalized management of BPH-related LUTS.
SN - 2950-4201
SN - 2950-3930
ER -